Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The stable introduction of a functional beta-globin gene in haematopoietic stem cells could be a powerful approach to treat beta-thalassaemia and sickle-cell disease. Genetic approaches aiming to increase normal beta-globin expression in the progeny of autologous haematopoietic stem cells might circumvent the limitations and risks of allogeneic cell transplants. However, low-level expression, position effects and transcriptional silencing hampered the effectiveness of viral transduction of the human beta-globin gene when it was linked to minimal regulatory sequences. Here we show that the use of recombinant lentiviruses enables efficient transfer and faithful integration of the human beta-globin gene together with large segments of its locus control region. In long-term recipients of unselected transduced bone marrow cells, tetramers of two murine alpha-globin and two human betaA-globin molecules account for up to 13% of total haemoglobin in mature red cells of normal mice. In beta-thalassaemic heterozygous mice higher percentages are obtained (17% to 24%), which are sufficient to ameliorate anaemia and red cell morphology. Such levels should be of therapeutic benefit in patients with severe defects in haemoglobin production.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After establishing that β-globin lentiviral vectors had successfully corrected models of β-thalassemia and sickle cell disease in mice, 17,18 we initiated a human clinical study of ex vivo gene therapy for the β-hemoglobinopathies”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [17]
Citations
Cites
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“, referred to as the locus control region (LCR), are linked to the globin gen”
BackgroundMalim, M. H., Hauber, J., Le, S.-Y., Maizel, J. V., & Cullen, B. R. (1989) · Nature · doi:10.1038/338254a0 · Cited by 1,280 · cited 1×
“Here we report how these problems may be overcome by using vectors derived from human immunodeficiency virus 1, a retrovirus that has the ability to regulate packaging of unspliced viral genome”
Hematology of Infancy and Childhood.
(1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-587_2 · Cited by 892
The Molecular Basis of Blood Diseases.
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-6-950_3 · Cited by 632
Miyoshi, H., Smith, K. A., Mosier, D. E., Verma, I. M., & Torbett, B. E. (1999) · Science · doi:10.1126/science.283.5402.682 · Cited by 624
The "beta-like-globin" gene domain in human erythroid cells.
Tuan, D., Solomon, W., Li, Q., & London, I. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6384 · Cited by 601 · cited 1×
“The same outcome prevails in transgenic mice unless genomic elements encompassing DNase I hypersensitive sites (HS) located 60 kilobases (kb) upstream of the human β-globin gen”
BackgroundLooping versus linking: toward a model for long-distance gene activation
Bulger, M., & Groudine, M. (1999) · Genes & Development · doi:10.1101/gad.13.19.2465 · Cited by 484
Raj, S. R., Chen, S. R. W., Sheldon, R. S., Shah, A. N., Kantharia, B. K., Salzer, U., Grimbacher, B., Leung, A. K. C., Kamat, D., Kolovou, G. D., et al. (2009) · Encyclopedia of Molecular Mechanisms of Disease · doi:10.1007/978-3-540-29676-8_1731 · Cited by 475
Cited by
Items 201–300 of 622
Lentiviral vectors ready for prime-time
Kohn, D. B. (2007) · Nature Biotechnology · doi:10.1038/nbt0107-65 · Cited by 42
Uchida, N., Washington, K. N., Lap, C. J. G., Hsieh, M. M., & Tisdale, J. F. (2010) · Molecular Therapy · doi:10.1038/mt.2010.218 · Cited by 41
Chow, C.-M., Athanassiadou, A., Raguz, S., Psiouri, L., Harland, L., Malik, M., Aitken, M. A., Grosveld, F. G., & Antoniou, M. N. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301654 · Cited by 41
Yamada, K., Olsen, J. C., Patel, M., Rao, K. W., & Walsh, C. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0287 · Cited by 41
Fetal gene therapy of α-thalassemia in a mouse model
Han, X.-D., Lin, C. J., Chang, J., Sadelain, M., & Kan, Y. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702457104 · Cited by 40
Self-citationPharmacological and molecular approaches for the treatment of β‐hemoglobin disorders
Lohani, N., Bhargava, N., Munshi, A., & Ramalingam, S. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26292 · Cited by 40
“The incorporation of critical LCR hypersensitive sites (HS) enhancers 2, 3, and 4 of human β-globin into the lentiviral vector led to achievement of therapeutic level of β-globin (May et al., 2000).”
BackgroundNegative regulation of γ-globin gene expression by cyclic AMP-dependent pathway in erythroid cells
Inoue, A., Kuroyanagi, Y., Terui, K., Moi, P., & Ikuta, T. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2003.12.006 · Cited by 40
Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice
Sii-Felice, K., Giorgi, M., Leboulch, P., & Payen, E. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.05.004 · Cited by 39
Current status of globin gene therapy for the treatment of β‐thalassaemia
Lisowski, L., & Sadelain, M. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07098.x · Cited by 39
“Over this period, haemoglobin levels in TNS9-treated animals averaged 65 ± 29 g/l. Southern blot analyses showed a mean VCN of 1Æ6 ± 0Æ6 in bone marrow and 1Æ2 ± 0Æ5 in blood (n = 6), thus indicating that TNS9 could generate 40 g/l haemoglobin per VC in this in vivo setting, an amount approximating half of hemizygous…”
BackgroundMethodResultInfluentialSelf-citationKang, E. M., Hsieh, M. M., Metzger, M. E., Krouse, A. E., Donahue, R. E., Sadelain, M., & Tisdale, J. F. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2005.10.010 · Cited by 39
“hematopoietic stem cell gene transfer techniques, recent progress in vector development has reinvigorated interest in clinical application [51–55].”
BackgroundSelf-citationMontiel-Equihua, C., Zhang, L., Knight, S., Saadeh, H., Scholz, S., Carmo, M., Alonso-Ferrero, M. E., Blundell, M. P., Monkeviciute, A., Schulz, R., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.50 · Cited by 39
Toward gene therapy for disorders of globin synthesis
Tisdale, J. F., & Sadelain, M. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90033-2 · Cited by 39
Self-citationDevelopment of Gene Therapy for Thalassemia
Nienhuis, A. W., & Persons, D. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011833 · Cited by 38
“Another advantage of lentiviral vectors is their well-developed mechanism for nuclearto-cytoplasmic transfer of unspliced mRNA, which facilitated the inclusion of globin genes with intact introns, LCR fragments, and insulator elements (May et al. 2000; Pawliuk et al. 2001).”
BackgroundHaematological Diseases in the Tropics
Thachil, J. V., Owusu‐Ofori, S., & Bates, I. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7020-5101-2.00066-2 · Cited by 38
Chang, A. H., Stephan, M. T., Lisowski, L., & Sadelain, M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.161 · Cited by 38
Self-citationUchida, N., Hargrove, P. W., Lap, C. J., Evans, M. E., Phang, O., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Nguyen, A.-D., Hsieh, M. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.159 · Cited by 36
eGFP reporter genes silence LCRβ-globin transgene expression via CpG dinucleotides
Dalle, B., Rubin, J. E., Alkan, O., Sukonnik, T., Pasceri, P., Yao, S., Pawliuk, R., Leboulch, P., & Ellis, J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.11.012 · Cited by 37
Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in β‐thalassemia
Sadelain, M., Rivière, I., Wang, X., Boulad, F., Prockop, S. E., Giardina, P. J., Maggio, A., Galanello, R., Locatelli, F., & Yannaki, E. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05597.x · Cited by 37
Self-citationAnimal models of β-hemoglobinopathies: utility and limitations
McColl, B., & Vadolas, J. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s87955 · Cited by 37
Gene therapy and gene editing strategies for hemoglobinopathies
Lidonnici, M. R., & Ferrari, G. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.12.001 · Cited by 36
Genome Editing for β-Hemoglobinopathies: Advances and Challenges
Frati, G., & Miccio, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030482 · Cited by 36
Gene therapy for sickle cell disease
Leonard, A. K., & Tisdale, J. F. (2023) · Hematology · doi:10.1182/hematology.2023000487 · Cited by 37
Pathophysiology and therapy for haemoglobinopathies; Part II: thalassaemias
Urbinati, F., Madigan, C., & Malik, P. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406010805 · Cited by 36
Kalle, C. V., Fehse, B., Layh‐Schmitt, G., Schmidt, M., Kelly, P. F., & Baum, C. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.07.007 · Cited by 36
Diverse Approaches to Gene Therapy of Sickle Cell Disease
White, S. L., Hart, K. L., & Kohn, D. B. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-021707 · Cited by 35
Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials
Segura, E., Ayoub, P. G., Hart, K. L., & Kohn, D. B. (2023) · Viruses · doi:10.3390/v15030713 · Cited by 35
“In 2000, the first successful therapeutic use of β-globin LV was demonstrated by Sadelain and colleagues [47].”
BackgroundRobust, Reversible Gene Knockdown Using a Single Lentiviral Short Hairpin RNA Vector
Brown, C. Y., Sadlon, T. J., Gargett, T., Melville, E. L., Zhang, R., Drabsch, Y., Ling, M., Strathdee, C. A., Gonda, T. J., & Barry, S. C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.107 · Cited by 35
“…lentiviral vectors offer several advantages over other viral vectors: they are more efficient at delivering complex gene expression cas-settes compared with other retroviral vectors (May et al. , 2000), they can mediate long-term gene expression (Seppen et al. , 2001), and they are relatively safe.”
RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors
Bell, A. J., Fegen, D., Ward, M., & Bank, A. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010053 · Cited by 35
Gene therapy for childhood immunological diseases
Kohn, D. B. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705895 · Cited by 35
Zhong, L., Li, W., Li, Y., Zhao, W., Wu, J., Li, B., Maina, N., Bischof, D., Qing, K., Weigel-Kelley, K. A., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.321 · Cited by 32
Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders
Uchida, N., Hsieh, M. M., Raines, L. N., Haro‐Mora, J. J., Demirci, S., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2019) · Nature Communications · doi:10.1038/s41467-019-12456-3 · Cited by 34
Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies
Paschoudi, K., Yannaki, E., & Psatha, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119527 · Cited by 34
Uchida, N., Fujita, A., Hsieh, M. M., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.029 · Cited by 34
An Optimized Lentiviral Vector Efficiently Corrects the Human Sickle Cell Disease Phenotype
Weber, L., Poletti, V., Magrin, E., Antoniani, C., Martin, S., Bayard, C., Sadek, H., Félix, T., Meneghini, V., Antoniou, M. N., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.012 · Cited by 34
Beauchemin, H., Blouin, M., & Trudel, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309989200 · Cited by 34
Gene Therapy for β-Thalassemia
Malik, P., & Arumugam, P. I. (2005) · Hematology · doi:10.1182/asheducation-2005.1.45 · Cited by 34
Gene Transfer into Nonhuman Primate Hematopoietic Stem Cells: Implications for Gene Therapy
Hanazono, Y., Terao, K., & Ozawa, K. (2001) · Stem Cells · doi:10.1634/stemcells.19-1-12 · Cited by 34
Prospects and problems of gene therapy: an update
Górecki, D. C. (2001) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.6.2.187 · Cited by 33
Yang, H., Qing, K., Keeler, G. D., Yin, L., Mietzsch, M., Ling, C., Hoffman, B. E., Agbandje‐McKenna, M., Tan, M., Wang, W., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.03.009 · Cited by 32
Gene therapy for sickle cell disease
Olowoyeye, A., & Okwundu, C. I. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007652.pub5 · Cited by 32
Therapeutic strategies in Sickle Cell Anemia: The past present and future
Fernandes, Q. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.03.025 · Cited by 32
Shangaris, P., Loukogeorgakis, S., Subramaniam, S., Flouri, C., Jackson, L. H., Wang, W., Blundell, M. P., Liu, S., Eaton, S., Bakhamis, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48078-4 · Cited by 32
Layon, M. E., Ackley, C. J., West, R. J., & Lowrey, C. H. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.094 · Cited by 32
Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges
Ghiaccio, V., Chappell, M., Rivella, S., & Breda, L. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00383-4 · Cited by 31
Self-citationRattananon, P., Anurathapan, U., Bhukhai, K., & Hongeng, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.730873 · Cited by 31
Development and clinical translation of ex vivo gene therapy
Wu, X., He, X., Liu, F., Jiang, X., Wang, P., Zhang, J., & Jiang, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.015 · Cited by 31
Advances in the gene therapy of monogenic blood cell diseases
Bueren, J. A., Bustamante, O. Q., Almarza, E., Navarro, S., Río, P., Segovia, J. C., & Güenechea, G. (2019) · Clinical Genetics · doi:10.1111/cge.13593 · Cited by 31
Evans, M., Kumkhaek, C., Hsieh, M. M., Donahue, R. E., Tisdale, J. F., & Uchida, N. (2013) · Molecular Therapy · doi:10.1038/mt.2013.256 · Cited by 31
Loewen, N. A., & Poeschla, E. M. (2005) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_007 · Cited by 31
Historical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy
Kohn, D. B. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.006 · Cited by 30
Fetal gene therapy: Opportunities and risks
Wagner, A. M., Schoeberlein, A., & Surbek, D. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.011 · Cited by 30
Alternative options for DNA-based experimental therapy of β-thalassemia
Gambari, R. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.665047 · Cited by 30
The beta‐globin locus control region versus gene therapy vectors: a struggle for expression
Ellis, J., & Pannell, D. (2001) · Clinical Genetics · doi:10.1034/j.1399-0004.2001.590103.x · Cited by 30
Recent advancements in gene therapy for sickle cell disease and β-thalassemia
Li, L., & Mandal, P. K. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1468952 · Cited by 29
Gene therapy as a new treatment option for inherited monogenic diseases
Boudes, P. F. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.009 · Cited by 29
Uchida, N., Haro‐Mora, J. J., Demirci, S., Fujita, A., Raines, L. N., Hsieh, M. M., & Tisdale, J. F. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.02.007 · Cited by 29
Future alternative therapies for β-thalassemia
Rivella, S., & Rachmilewitz, E. A. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.56 · Cited by 29
Self-citationGenetic manipulation of hematopoietic stem cells
Larochelle, A., & Dunbar, C. E. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.07.002 · Cited by 29
Gene therapy for inherited disorders of haematopoietic cells
Klein, C., & Baum, C. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200366 · Cited by 29
Mazurier, F., Géronimi, F., Lamrissi‐Garcia, I., Morel, C., Richard, E., Ged, C., Fontanellas, A., Moreau‐Gaudry, F., Morey, M., & de Verneuil, H. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0270 · Cited by 29
The GATA1-HS2 Enhancer Allows Persistent and Position-Independent Expression of a β-globin Transgene
Miccio, A., Poletti, V., Tiboni, F., Rossi, C., Antonelli, A., Mavilio, F., & Ferrari, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027955 · Cited by 28
“. Gene therapy, i.e., transplantation of autologous, genetically corrected hematopoietic stem cells (HSCs), is a potential alternative for patients lacking a compatible donor. Gene therapy of β-thalassemia requires efficient transfer and appropriately regulated expression of a β-globin transgene. Lentiviral vectors (L…”
BackgroundIn vivo activation of the human -globin gene: the therapeutic potential in -thalassemic mice
Manchinu, M. F., Marongiu, M. F., Poddie, D., Casu, C., Latini, V., Simbula, M., Galanello, R., Moi, P., Cao, A., Porcu, S., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.082768 · Cited by 28
Fischer, A., Hacein‐Bey‐Abina, S., Lagresle‐Peyrou, C., Garrigue, A., & Cavazzana, M. (2005) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)33504-6 · Cited by 28
Promise of gene therapy to treat sickle cell disease
Romero, Z. G., DeWitt, M. A., & Walters, M. C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1536119 · Cited by 29
Partial correction of murine β-thalassemia with a gammaretrovirus vector for human γ-globin
Nishino, T., Tubb, J., & Emery, D. W. (2006) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2006.05.001 · Cited by 28
Kowolik, C. M., Hu, J. X., & Yee, J. (2001) · Journal of Virology · doi:10.1128/jvi.75.10.4641-4648.2001 · Cited by 28
Advances in Predictive, Preventive and Personalised Medicine
Karabulut, S. (2012) · Cited by 27
A preclinical approach for gene therapy of β‐thalassemia
Breda, L., Kleinert, D. A., Casu, C., Casula, L., Cartegni, L., Fibach, E., Mancini, I., Giardina, P. J., Gambari, R., & Rivella, S. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05594.x · Cited by 27
Self-citationProduction of Transgenic Pigs Mediated by Pseudotyped Lentivirus and Sperm
Zhang, Y., Xi, Q., Ding, J., Cai, W., Meng, F., Zhou, J.-Y., Li, H., Jiang, Q., Shu, G., Wang, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035335 · Cited by 27
“have indicated that genetic mosaicism occurs using lentiviral vectors. May et al.”
BackgroundGene therapy for immunodeficiency diseases
Fischer, A., Hacein‐Bey‐Abina, S., & Cavazzana, M. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.07.003 · Cited by 27
Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells
Sadelain, M., Frassoni, F., & Rivière, I. (2000) · Current Opinion in Hematology · doi:10.1097/00062752-200011000-00008 · Cited by 27
Self-citationGene Therapy Through Autologous Transplantation of Gene-Modified Hematopoietic Stem Cells
Kohn, D. B., Pai, S., & Sadelain, M. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.09.021 · Cited by 26
Self-citationLidonnici, M. R., Paleari, Y., Tiboni, F., Mandelli, G., Rossi, C., Vezzoli, M., Aprile, A., Lederer, C. W., Ambrosi, A., Chanut, F. J.-A., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.09.001 · Cited by 26
Lentiviral Transduction of Immune Cells
Swainson, L. A., Mongellaz, C., Adjali, O., Vicente, R., & Taylor, N. N. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-570-1_18 · Cited by 26
Allogeneic cellular and autologous stem cell therapy for sickle cell disease: ‘whom, when and how’
Freed, J., Talano, J., Small, T. N., Ricci, A. M., & Cairo, M. S. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.245 · Cited by 26
Zuccato, C., Breda, L., Salvatori, F., Breveglieri, G., Gardenghi, S., Bianchi, N., Brognara, E., Lampronti, I., Borgatti, M., Rivella, S., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1430-5 · Cited by 26
Self-citationNovel Therapeutic Approaches in Sickle Cell Disease
Walters, M. C., Nienhuis, A. W., & Vichinsky, E. P. (2002) · Hematology · doi:10.1182/asheducation-2002.1.10 · Cited by 26
Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Siatskas, C., Chan, J. M. K., Field, J., Murphy, K., Nasa, Z., Toh, B., & Alderuccio, F. (2006) · Current Gene Therapy · doi:10.2174/156652306775515600 · Cited by 26
Recent advances in gene therapy for thalassemia
Gokani, R., Raja, J., & Rachchh, M. (2012) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.99020 · Cited by 26
Oh, I., Fabry, M. E., Humphries, R. K., Pawliuk, R., Leboulch, P., Hoffman, R., Nagel, R. L., & Eaves, C. J. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.02.001 · Cited by 26
Indraccolo, S., Minuzzo, S. A., Roccaforte, F., Zamarchi, R., Habeler, W., Stievano, L., Tosello, V., Klein, D., Günzburg, W. H., Basso, G., et al. (2001) · Blood · doi:10.1182/blood.v98.13.3607 · Cited by 26
Gene Therapy in Thalassemia and Hemoglobinopathies
Breda, L., Gambari, R., & Rivella, S. (2009) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2009.008 · Cited by 25
Self-citationSellner, L., Stiefelhagen, M., Kleinschmidt, J. A., Laufs, S., Wenz, F. K., Früehauf, S., Zeller, W. J., & Veldwijk, M. R. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.03.007 · Cited by 25
Hanawa, H., Persons, D. A., & Nienhuis, A. W. (2002) · Human Gene Therapy · doi:10.1089/10430340260395866 · Cited by 25
Hematopoietic stem cell gene therapy: selecting only the best
Bank, A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci20336 · Cited by 25
Quality of life and survival of patients with beta-thalassemia major.
Cao, A. (2004) · PubMed · Cited by 25
Nègre, O., Fusil, F., Colomb, C., Roth, S. L., Gillet-Legrand, B., Henri, A., Beuzard, Y., Bushman, F. D., Leboulch, P., & Payen, E. (2011) · Blood · doi:10.1182/blood-2010-01-263582 · Cited by 25
Hematopoietic Stem Cell Gene Therapy
Emery, D. W., Nishino, T., Murata, K., Fragkos, M., & Stamatoyannopoulos, G. (2002) · International Journal of Hematology · doi:10.1007/bf02982035 · Cited by 25
A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies
Zittersteijn, H. A., Harteveld, C. L., Klaver-Flores, S., Lankester, A. C., Hoeben, R. C., Staal, F. J. T., & Gonçalves, M. A. F. V. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617780 · Cited by 24
“For instance, concerning the optimization of LCR elements in particular, it was demonstrated that incorporating in LV genomes large sequences spanning the HS2, HS3 and HS4 elements, instead of the respective minimal core sequences, yielded sustained and high amounts of recombinant β-globin in RBCs of transplanted mice…”
BackgroundLentivirus Vectors in β-Thalassemia
Payen, E., Colomb, C., Nègre, O., Beuzard, Y., Hehir, K. M., & Leboulch, P. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00006-5 · Cited by 24
Gene therapy for β-thalassaemia: the continuing challenge
Yannaki, E., Emery, D. W., & Stamatoyannopoulos, G. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001626 · Cited by 24
Gene Therapy and Genome Editing
Boulad, F., Mansilla‐Soto, J., Cabriolu, A., Rivière, I., & Sadelain, M. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.11.007 · Cited by 24
Self-citationSrinivasakumar, N. (2001) · Somatic Cell and Molecular Genetics · doi:10.1023/a:1021074613196 · Cited by 24
Kelly, P. F., Donahue, R. E., Vandergriff, J. A., Takatoku, M., Bonifacino, A. C., Agricola, B. A., Metzger, M. E., Dunbar, C. E., Nienhuis, A. W., & Vanin, E. F. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/s1079-9796(03)00005-6 · Cited by 24
Kim, Y., Wielgosz, M. M., Hargrove, P. W., Kepes, S., Gray, J. T., Persons, D. A., & Nienhuis, A. W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.48 · Cited by 23
Breda, L., Ghiaccio, V., Tanaka, N., Jarocha, D. J., Ikawa, Y., Abdulmalik, O. Y., Dong, A., Casu, C., Raabe, T. D., Shan, X., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.036 · Cited by 23
Self-citationCombining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia
Breda, L., Rivella, S., Zuccato, C., & Gambari, R. (2013) · Expert Review of Hematology · doi:10.1586/ehm.13.24 · Cited by 22
Self-citationGene Therapy for Hemoglobinopathies: Tremendous Successes and Remaining Caveats
Malik, P. (2016) · Molecular Therapy · doi:10.1038/mt.2016.57 · Cited by 22
Mouse models in hematopoietic stem cell gene therapy and genome editing
Radtke, S., Humbert, O., & Kiem, H. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113692 · Cited by 22
Hematoprotection by Transfer of Drug-Resistance Genes
Flaßhove, M., Moritz, T., Bardenheuer, W., & Seeber, S. (2003) · Acta Haematologica · doi:10.1159/000072458 · Cited by 22
“More recently, promising constructs on the basis of lentiviruses such as HIV have been reported and might help to overcome some of the problems unsolved by conventional retroviral vectors, e.g. the low transduction efficiency for quiescent stem cells [ ,”
Background
Metadata
- Authors
- May, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of California, San Francisco (US)
- Corresponding author
- Sadelain, Michel
- Venue
- Nature
- Published
- 2000-07
- Volume
- 406
- Issue
- 6791
- Pages
- 82-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1997170085
- Cited by
- 567
- References
- 34
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 6 · 2023: 11 · 2022: 11 · 2021: 10 · 2020: 10 · 2019: 16 · 2018: 26 · 2017: 18 · 2016: 16 · 2015: 15 · 2014: 13 · 2013: 22 · 2012: 24
- FWCI
- 24.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- James S. McDonnell Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- beta-thalassemia, sickle cell disease, lentiviral transduction, human beta-globin gene, hematopoietic stem cells, locus control region, hemoglobin synthesis, anemia, erythrocyte morphology, position effect, transcriptional silencing
- MeSH terms
- Animals, Cell Line, Female, Genetic Vectors, Globins, Hemoglobins, Humans, Male, Recombinant Proteins, Transduction, Genetic, Genetic Therapy, HIV-1, Bone Marrow Transplantation, Lentivirus, beta-Thalassemia, Gene Transfer Techniques, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.